Zafgen finally breaks its silence, says it’s probing death of a patient

John Carroll

More than two days after 's stock started to get crushed under the heavy weight of speculation surrounding its sudden decision to cancel a roadshow presentation to investors, the biotech has revealed that a died in its late-stage study of its lead obesity drug for Prader-Willi syndrome.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS